EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency

Interventions

DRUG

EIS-12656

EIS-12656 tablets given daily

DRUG

Olaparib

as per USPI/SmPC

DRUG

Trastuzumab deruxtecan

as per USPI/SmPC

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston